TLE3 as a marker for chemotherapy
AssigneeClarient Diagnostic Services, Inc.
InventorsBrian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
Life of this patent
Estimating the term…
Abstract
Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
Claims30
A method of treating breast, lung or ovarian cancer in a patient comprising administering to the patient in need thereof a taxane, wherein the patient's cancer has been previously identified to express TLE3 polypeptide.
A method of treating breast, lung, or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.
A method of treating breast cancer in a patient, wherein the patient is triple negative for estrogen receptor, progesterone receptor, and HER-2 markers and the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.
A method of treating lung or ovarian cancer in a patient, wherein the cancer has been identified as positive for TLE3 polypeptide expression, the method comprising administering a taxane to the patient.
Dependencies are inferred from the claim text.